Gastrinoma and Zollinger Ellison syndrome: A roadmap for the management between new and old therapies

Figure 2 A proposed therapeutic algorithm is represented based on both evidence from literature and personal own experience. ¹Allocation driving prognostic factors are performance status, age, metastatic disease burden and pattern, comorbidities. CT: Computed tomography; dNEN: Duodenal neuroendocrine neoplasm; EUS: Endoscopic ultrasound; H2: Histamine receptor 2: LT: Orthotopic liver transplantation; MEN-1: Multiple endocrine neoplasia type 1; MRI: Magnetic resonance imaging; PET: Positron emission tomography; pNEN: Pancreatic NEN; PPIs: Proton pump inhibitors; PRRT: Peptide-radioreceptor therapy; SSAs: Somatostatin analogs; TACE: Transarterial chemoembolization; TARE: Transarterial radioembolization; ZES: Zollinger Ellison syndrome.